Tag results:

myeloid cells

Therapeutic Inhibition of USP9x-Mediated Notch Signaling in Triple-Negative Breast Cancer

[Proceedings of the National Academy of Sciences of the United States of America] Using a murine TNBC model, scientists showed that USP9x knockdown abrogated Notch activation, reducing the production of the proinflammatory cytokines, C-C motif chemokine ligand 2 and interleukin-1 beta.

US FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

[BeiGene, Ltd.] BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.

Posttranslational Modifications by ADAM10 Shape Myeloid Antigen-Presenting Cell Homeostasis in the Splenic Marginal Zone

[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified the cell-surface–expressed A-disintegrin-and-metalloproteinase 10 as an essential regulator of conventional dendritic cell (cDC)1 and cDC2 homeostasis in the splenic marginal zone.

Chronic Mineral Oil Administration Increases Hepatic Inflammation in Wild Type Mice Compared to Lipocalin 2 Null Mice

[Laboratory Investigation] Scientists investigated the roles of Lipocalin 2 (LCN2) in chronic inflammation and fibrosis, using repeated carbon tetrachloride in mineral-oil injection. Hepatic and serum LCN2 levels were remarkably higher in the mineral oil-injected wild type group compared to the CCl4.

Mesenchymal Stromal Cells as Carriers of IL-12 Reduce Primary and Metastatic Tumors of Murine Melanoma

[Scientific Reports] Scientists developed a system in which cytokine may be administered intravenously without toxic side effects. MSC were used as carriers of the IL-12.

Clinical and Biological Aspects of Myeloid Leukemia in Down Syndrome

[Leukemia] Despite advances in understanding the clinical and biological aspects of myeloid leukemia in children with Down syndrome (DS), little is known about the mechanisms of relapse. Upon relapse, patients face a poor outcome, and there is no consensus on treatment. Future studies need to be focused on this challenging aspect of leukemia in children with DS.

Popular